A Phase 1/2 interventional study of BMS-986012 (anti-fucosyl-GM1) and Nivolumab in Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.
Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2014, is one of 2 in phase 1/2, and was the 9th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, China, Italy and 3 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 23 more countries
Ages 18+
By country, each count listing its studies:
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 3
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 92 across the 17 interventional studies, 3,485 across the 2 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
Biological: BMS-986012 (anti-fucosyl-GM1)
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab
BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
Biological: BMS-986012 (anti-fucosyl-GM1) · Biological: Nivolumab
Number of Participants With Adverse Events (AEs)
Number of participants with any grade adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 100 days post last dose (Up to 64 months)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants with any grade serious adverse events (SAEs). A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 100 days post last dose (Up to 64 months)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation
Number of participants with any grade adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 100 days post last dose (Up to 64 months)
Number of Participants Who Died
Number of participants who died due to any cause.
Time frame: From first dose to 100 days post last dose (Up to 64 months)
Number of Participants With Abnormal Hepatic Test
Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 5xULN, \> 3xULN, and \> 2xULN * Any of ALT, AST, Total Bilirubin or ALP \> 8xULN * Total bilirubin \> 3xULN ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal
Time frame: From first dose to 100 days post last dose (Up to 64 months)
BMS-986012 Maximum Observed Serum Concentration (Cmax)
BMS-986012 maximum observed serum concentration (Cmax).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Time of Maximum Observed Serum Concentration (Tmax)
BMS-986012 time of maximum observed serum concentration (Tmax).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
BMS-986012 Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC (0-T))
BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Area Under the Serum Concentration-time Curve in One Dosing Interval AUC (TAU)
BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Observed Serum Concentration at the End of a Dosing Interval (Ctau)
BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Total Body Clearance (CLT)
BMS-986012 total body clearance (CLT).
Time frame: Cycle 1 day 1, cycle 3 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Trough Observed Serum Concentration (Ctrough)
BMS-986012 trough observed serum concentration (Ctrough).
Time frame: Cycle 2 day 1, cycle 3 day 1, cycle 4 day 1, cycle 7 day 1, cycle 11 day 1. cycle 15 day 1 (including pre-dose, 1, 2, 4, 8, 24, 72, 168, 336 hours post dose)
BMS-986012 Average Concentration Over a Dosing Interval (Css-avg)
BMS-986012 Average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css-avg).
Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
BMS-986012 Accumulation Index (AI_AUC)
BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.
Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
BMS-986012 Cmax Accumulation Index (AI_Cmax)
BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.
Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
BMS-986012 Ctau Accumulation Index (AI_Ctau)
BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.
Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
BMS-986012 Effective Elimination (T-HALFeff)
BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.
Time frame: Cycle 3 day 1 (including pre-dose, 1, 2, 4, and 8 hours post dose)
Best Overall Response (BOR)
BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
Time frame: From first dose to the last tumor assessment prior to subsequent therapy (Up to 97 months)
Objective Response Rate (ORR)
ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
Time frame: From first dose date to the date of first documented disease progression (Up to 97 months)
Duration of Response (DoR)
DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.
Time frame: From the date of first dose to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 97 months)
Progression Free Survival (PFS)
PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose. Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
Time frame: From first dose to the date of first documented disease progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose (Up to 97 months)
Progression Free Survival Rate (PFSR)
PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72). Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
Time frame: Weeks 12, 24, 36, 48, 60, 72
Number of Participants With Anti-BMS-986012 Antibodies (ADA)
Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.
Time frame: From first dose to 100 days following the last BMS-986012 dose (Up to 64 months)
| Milestone | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 29 | 35 | 21 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 29 | 35 | 21 | 8 |
| Withdrew: Disease progression | 7 | 4 | 26 | 31 | 16 | 6 |
| Withdrew: Study drug toxicity | 0 | 1 | 1 | 1 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 | 0 | 0 |
Number of participants with any grade adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 7 | 6 | 29 | 35 | 21 | 8 |
Number of participants with any grade serious adverse events (SAEs). A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 7 | 4 | 21 | 24 | 11 | 5 |
Number of participants with any grade adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) Leading to Discontinuation | 0 | 1 | 2 | 5 | 3 | 2 |
Number of participants who died due to any cause.
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Died | 3 | 2 | 10 | 16 | 2 | 4 |
Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 5xULN, \> 3xULN, and \> 2xULN * Any of ALT, AST, Total Bilirubin or ALP \> 8xULN * Total bilirubin \> 3xULN ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| ALT OR AST > 5XULN | 0 | 0 | 0 | 1 | 1 | 2 |
| ALT OR AST > 3XULN | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT OR AST > 2XULN | 0 | 0 | 0 | 0 | 0 | 0 |
| ANY OF ALT, AST, TOTAL BILIRUBIN OR ALP > 8XULN | 0 | 0 | 0 | 1 | 0 | 1 |
| TOTAL BILIRUBIN > 3XULN | 1 | 0 | 0 | 0 | 0 | 1 |
BMS-986012 maximum observed serum concentration (Cmax).
| ug/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 27.5 ± 31 | 53.8 ± 28 | 121 ± 26 | 276 ± 37 | 111 ± 33 | 339 ± 25 |
| cycle 3 day 1 | 33.8 ± NA | 46.9 ± NA | 221 ± 1 | 279 ± 37 | — | — |
BMS-986012 time of maximum observed serum concentration (Tmax).
| hours | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 2.08 (1.00 to 8.00) | 2.02 (1.00 to 6.33) | 2.00 (1.00 to 6.07) | 1.58 (0.950 to 4.40) | 4.00 (1.00 to 5.40) | 1.53 (1.00 to 4.30) |
| cycle 3 day 1 | 1.93 (1.93 to 1.93) | 4.00 (4.00 to 4.00) | 2.04 (2.02 to 2.07) | 2.30 (2.05 to 4.00) | — | — |
BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).
| h*ug/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 3997 ± 31 | 5584 ± 55 | 18456 ± 32 | 36223 ± 40 | 16527 ± 31 | 45126 ± 24 |
| cycle 3 day 1 | 7062 ± NA | 10560 ± NA | 42583 ± 8 | 58649 ± 28 | — | — |
BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).
| h*ug/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 4300 ± 29 | 8356 ± 28 | 19865 ± 28 | 40979 ± 34 | 18161 ± 30 | 49031 ± 26 |
| cycle 3 day 1 | 7062 ± NA | 10560 ± NA | 42583 ± 8 | 62634 ± 33 | — | — |
BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).
| ug/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 3.44 ± 38 | 6.24 ± 31 | 17.4 ± 32 | 30.2 ± 59 | 14.6 ± 44 | 39.5 ± 40 |
| cycle 3 day 1 | 7.39 ± NA | 13.6 ± NA | 42.4 ± 13 | 59.2 ± 19 | — | — |
BMS-986012 total body clearance (CLT).
| mL/h | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 1 day 1 | 16.3 ± 38 | 19.1 ± 27 | 20.1 ± 24 | 24.4 ± 86 | 22.0 ± 30 | 20.4 ± 28 |
| cycle 3 day 1 | 9.91 ± NA | 15.2 ± NA | 9.39 ± 8 | 16.0 ± 40 | — | — |
BMS-986012 trough observed serum concentration (Ctrough).
| ng/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| cycle 2 day 1 | 4186 ± 27 | 7211 ± 17 | 18810 ± 29 | 36990 ± 54 | 14544 ± 84 | 36391 ± 43 |
| cycle 3 day 1 | 6570 ± NA | 9100 ± NA | 29232 ± 36 | 68589 ± 57 | 26016 ± 37 | 158801 ± 85 |
| cycle 4 day 1 | 7390 ± NA | 13600 ± NA | 35122 ± 26 | 90207 ± 68 | 26102 ± 63 | 157000 ± NA |
| cycle 7 day 1 | 9040 ± NA | 13700 ± NA | 38315 ± 27 | 107444 ± 58 | 38405 ± 9 | — |
| cycle 11 day 1 | 9930 ± NA | — | 32251 ± 14 | 102980 ± 67 | 34400 ± NA | — |
| cycle 15 day 1 | 8029 ± NA | — | — | — | — | — |
BMS-986012 Average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css-avg).
| ug/mL | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| BMS-986012 Average Concentration Over a Dosing Interval (Css-avg) | 13.9 ± NA | 22.0 ± NA | 82.1 ± 11 | 119 ± 33 | — | — |
BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.
| Ratio | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| BMS-986012 Accumulation Index (AI_AUC) | 1.56 ± NA | 1.55 ± NA | 1.62 ± 22 | 1.39 ± 51 | — | — |
BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.
| Ratio | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| BMS-986012 Cmax Accumulation Index (AI_Cmax) | 0.994 ± NA | 1.47 ± NA | 1.22 ± 11 | 0.940 ± 70 | — | — |
BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.
| Ratio | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| BMS-986012 Ctau Accumulation Index (AI_Ctau) | 1.81 ± NA | 2.31 ± NA | 1.76 ± 0 | 1.08 ± 82 | — | — |
BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.
| Hours | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| BMS-986012 Effective Elimination (T-HALFeff) | 342 ± NA | 319 ± NA | 384 ± 154.2 | 583 ± NA | — | — |
BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Complete Response | 1 | 0 | 0 | 0 | 1 | 0 |
| Partial Response | 0 | 0 | 1 | 1 | 8 | 2 |
| Stable Disease | 0 | 2 | 8 | 8 | 2 | 1 |
| Progressive Disease | 4 | 2 | 18 | 21 | 9 | 3 |
| Not evaluable | 2 | 2 | 2 | 5 | 1 | 2 |
ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
| Percent of participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 14.3 (0.4 to 57.9) | 0 (0.0 to 45.9) | 3.4 (0.1 to 17.8) | 2.9 (0.1 to 14.9) | 42.9 (21.8 to 66.0) | 25.0 (3.2 to 65.1) |
DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.
| Weeks | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Duration of Response (DoR) | — | — | — | — | 120.57 (12.14 to NA) | — |
PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose. Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
| Weeks | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 5.50 (2.43 to 53.00) | 5.86 (5.29 to 30.29) | 5.79 (5.57 to 8.00) | 5.36 (5.00 to 5.71) | 17.71 (6.14 to 120.29) | 5.71 (2.71 to 25.00) |
PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72). Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm
| Percent of participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Week 12 | NA (NA to NA) | NA (NA to NA) | 21.4 (8.7 to 37.8) | 20.6 (9.1 to 35.3) | 55.0 (31.3 to 73.5) | NA (NA to NA) |
| Week 24 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 45.0 (23.1 to 64.7) | NA (NA to NA) |
| Week 36 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 45.0 (23.1 to 64.7) | NA (NA to NA) |
| Week 48 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 35.0 (15.7 to 55.2) | NA (NA to NA) |
| Week 60 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 35.0 (15.7 to 55.2) | NA (NA to NA) |
| Week 72 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 35.0 (15.7 to 55.2) | NA (NA to NA) |
Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.
| Participants | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg |
|---|---|---|---|---|---|---|
| Baseline ADA positive | 0 | 0 | 0 | 1 | 0 | 0 |
| ADA positive | 0 | 0 | 0 | 0 | 0 | 0 |
| ADA negative | 5 | 5 | 27 | 25 | 14 | 7 |
Collected over SAEs and Other AEs are assessed from first dose up to 100 days post last dose (Up to 64 months). Participants were assessed for all-cause mortality from their first dose to their study completion (Up to 97 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS 70mg SCLC Refractory | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| BMS 70mg SCLC Sensitive | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) |
| BMS 160mg SCLC Refractory | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| BMS 160mg SCLC Sensitive | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| BMS 400mg SCLC Refractory | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| BMS 400mg SCLC Sensitive | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| BMS 400mg SCLC Refractory Expansion | 9/12 (75%) | 8/12 (66.7%) | 12/12 (100%) |
| BMS 400mg SCLC Sensitive Expansion | 9/10 (90%) | 6/10 (60%) | 10/10 (100%) |
| BMS 1000mg SCLC Refractory | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| BMS 1000mg SCLC Sensitive | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| BMS 1000mg SCLC Refractory Expansion | 11/12 (91.7%) | 8/12 (66.7%) | 12/12 (100%) |
| BMS 1000mg SCLC Sensitive Expansion | 12/14 (85.7%) | 11/14 (78.6%) | 14/14 (100%) |
| BMS 400mg + Nivo 360mg SCLC Refractory | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| BMS 400mg + Nivo 360mg SCLC Sensitive | 6/6 (100%) | 4/6 (66.7%) | 6/6 (100%) |
| BMS 400mg + Nivo 360mg SCLC Refractory Expansion | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| BMS 400mg + Nivo 360mg SCLC Sensitive Expansion | 4/9 (44.4%) | 4/9 (44.4%) | 9/9 (100%) |
| BMS 1000mg + Nivo 360mg SCLC Refractory | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| BMS 1000mg + Nivo 360mg SCLC Sensitive | 5/5 (100%) | 2/5 (40%) | 5/5 (100%) |
| Event | BMS 70mg SCLC Refractory | BMS 70mg SCLC Sensitive | BMS 160mg SCLC Refractory | BMS 160mg SCLC Sensitive | BMS 400mg SCLC Refractory | BMS 400mg SCLC Sensitive | BMS 400mg SCLC Refractory Expansion | BMS 400mg SCLC Sensitive Expansion | BMS 1000mg SCLC Refractory | BMS 1000mg SCLC Sensitive | BMS 1000mg SCLC Refractory Expansion | BMS 1000mg SCLC Sensitive Expansion | BMS 400mg + Nivo 360mg SCLC Refractory | BMS 400mg + Nivo 360mg SCLC Sensitive | BMS 400mg + Nivo 360mg SCLC Refractory Expansion | BMS 400mg + Nivo 360mg SCLC Sensitive Expansion | BMS 1000mg + Nivo 360mg SCLC Refractory | BMS 1000mg + Nivo 360mg SCLC Sensitive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 3/4 | 1/2 | 2/4 | 2/3 | 1/4 | 5/12 | 3/10 | 3/3 | 1/6 | 6/12 | 6/14 | 0/2 | 3/6 | 1/4 | 1/9 | 2/3 | 2/5 |
| Pericardial effusionCardiac disorders | 0/3 | 1/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 1/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| FatigueGeneral disorders | 0/3 | 2/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| PainGeneral disorders | 0/3 | 0/4 | 1/2 | 0/4 | 1/3 | 0/4 | 0/12 | 0/10 | 1/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| Diarrhoea infectiousInfections and infestations | 0/3 | 0/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 1/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| Enterocolitis infectiousInfections and infestations | 0/3 | 0/4 | 1/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| Gastric haemorrhageGastrointestinal disorders | 0/3 | 0/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 1/3 | 0/5 |
| Oedema peripheralGeneral disorders | 1/3 | 0/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 0/2 | 0/4 | 1/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 0/3 | 0/5 |
| Hepatic failureHepatobiliary disorders | 0/3 | 0/4 | 0/2 | 0/4 | 0/3 | 0/4 | 0/12 | 0/10 | 0/3 | 0/6 | 0/12 | 0/14 | 0/2 | 0/6 | 0/4 | 0/9 | 1/3 | 0/5 |
| Event | BMS 70mg SCLC Refractory | BMS 70mg SCLC Sensitive | BMS 160mg SCLC Refractory | BMS 160mg SCLC Sensitive | BMS 400mg SCLC Refractory | BMS 400mg SCLC Sensitive | BMS 400mg SCLC Refractory Expansion | BMS 400mg SCLC Sensitive Expansion | BMS 1000mg SCLC Refractory | BMS 1000mg SCLC Sensitive | BMS 1000mg SCLC Refractory Expansion | BMS 1000mg SCLC Sensitive Expansion | BMS 400mg + Nivo 360mg SCLC Refractory | BMS 400mg + Nivo 360mg SCLC Sensitive | BMS 400mg + Nivo 360mg SCLC Refractory Expansion | BMS 400mg + Nivo 360mg SCLC Sensitive Expansion | BMS 1000mg + Nivo 360mg SCLC Refractory | BMS 1000mg + Nivo 360mg SCLC Sensitive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/3 | 4/4 | 1/2 | 1/4 | 2/3 | 1/4 | 2/12 | 3/10 | 2/3 | 2/6 | 7/12 | 5/14 | 1/2 | 2/6 | 2/4 | 4/9 | 1/3 | 3/5 |
| FatigueGeneral disorders | 2/3 | 3/4 | 0/2 | 1/4 | 0/3 | 1/4 | 4/12 | 3/10 | 0/3 | 3/6 | 7/12 | 12/14 | 1/2 | 2/6 | 4/4 | 4/9 | 2/3 | 2/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/3 | 1/4 | 0/2 | 1/4 | 0/3 | 1/4 | 3/12 | 1/10 | 0/3 | 0/6 | 2/12 | 1/14 | 1/2 | 2/6 | 2/4 | 9/9 | 1/3 | 3/5 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 0/4 | 1/2 | 1/4 | 2/3 | 0/4 | 1/12 | 4/10 | 0/3 | 2/6 | 4/12 | 2/14 | 2/2 | 3/6 | 1/4 | 3/9 | 0/3 | 2/5 |
| HeadacheNervous system disorders | 0/3 | 2/4 | 0/2 | 1/4 | 0/3 | 2/4 | 0/12 | 1/10 | 1/3 | 0/6 | 2/12 | 1/14 | 2/2 | 2/6 | 1/4 | 0/9 | 1/3 | 2/5 |
| PruritusSkin and subcutaneous tissue disorders | 2/3 | 4/4 | 2/2 | 2/4 | 3/3 | 4/4 | 12/12 | 8/10 | 3/3 | 6/6 | 9/12 | 13/14 | 1/2 | 5/6 | 4/4 | 9/9 | 3/3 | 5/5 |
| ConstipationGastrointestinal disorders | 1/3 | 3/4 | 1/2 | 1/4 | 1/3 | 1/4 | 5/12 | 6/10 | 2/3 | 1/6 | 2/12 | 3/14 | 0/2 | 2/6 | 1/4 | 4/9 | 2/3 | 1/5 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/3 | 0/4 | 0/2 | 0/4 | 0/3 | 3/4 | 2/12 | 0/10 | 0/3 | 0/6 | 4/12 | 0/14 | 1/2 | 0/6 | 0/4 | 3/9 | 0/3 | 1/5 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 1/4 | 1/2 | 1/4 | 1/3 | 2/4 | 6/12 | 7/10 | 1/3 | 2/6 | 5/12 | 6/14 | 0/2 | 2/6 | 2/4 | 1/9 | 2/3 | 1/5 |
| Oedema peripheralGeneral disorders | 0/3 | 1/4 | 0/2 | 0/4 | 2/3 | 0/4 | 1/12 | 2/10 | 1/3 | 0/6 | 4/12 | 2/14 | 1/2 | 2/6 | 0/4 | 2/9 | 0/3 | 1/5 |
| Age, Continuous(Years) | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 65.1 ± 10.6 | 58.3 ± 8.1 | 64.4 ± 9.2 | 61.7 ± 9.5 | 62.1 ± 9.8 | 61.1 ± 7.3 | 62.5 ± 9.3 |
| Sex: Female, Male(Participants) | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 11 | 12 | 9 | 5 | 45 |
| Male | 3 | 2 | 18 | 23 | 12 | 3 | 61 |
| Ethnicity (NIH/OMB)(Participants) | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 1 | 0 | 3 |
| Not Hispanic or Latino | 6 | 6 | 26 | 33 | 20 | 8 | 99 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 | 0 | 0 | 4 |
| Race (NIH/OMB)(Participants) | BMS 70mg | BMS 160mg | BMS 400mg | BMS 1000mg | BMS 400mg + Nivo 360mg | BMS 1000mg + Nivo 360mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 3 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 7 | 6 | 27 | 30 | 21 | 8 | 99 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Dec 2022, 97 months.
Results were first posted in Mar 2024, 1 year 2 months after primary completion.
Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's 97 months is above that.
Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atigotatug